Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease
- 1 August 1987
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 1 (4), 273-280
- https://doi.org/10.1111/j.1365-2036.1987.tb00627.x
Abstract
Gastrointestinal transit of an enteric coated delayed release 5-aminosalicylic acid tablet radiolabelled with III indium has been monitored in a total of 13 patients with Crohn's disease and ulcerative colitis. More than 70% of the tablets disintegrated in the small intestine, on average 3.2 hours after emptying from the stomach. Dispersed preparation was detected in the proximal colon of all the patients, except one with an ileostomy. Mean peak plasma concentrations of 5-aminosalicylic acid and its metabolite acetyl-5-aminosalicylic acid occurred 3–4 hours after gastric emptying. The tablets provide a reliable means of drug delivery to the ileum and proximal colon.Keywords
This publication has 9 references indexed in Scilit:
- Gastrointestinal transit of an enteric‐coated delayed‐release 5‐aminosalicylic acid tabletAlimentary Pharmacology & Therapeutics, 1987
- Exercise and small intestinal transitNuclear Medicine Communications, 1987
- Transit of pharmaceutical dosage forms through the small intestine.Gut, 1986
- Whole-bowel transit in patients with the irritable bowel syndromeEuropean Journal of Nuclear Medicine and Molecular Imaging, 1986
- Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.Gut, 1985
- Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.BMJ, 1983
- 5-Aminosalicylic Acid in a Slow-Release Preparation: Bioavailability, Plasma Level, and Excretion in HumansGastroenterology, 1982
- Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's DiseaseNew England Journal of Medicine, 1980